{"id":19867,"date":"2026-05-27T06:58:40","date_gmt":"2026-05-27T06:58:40","guid":{"rendered":"https:\/\/legaladvantage.net\/?p=19867"},"modified":"2026-05-27T07:07:11","modified_gmt":"2026-05-27T07:07:11","slug":"antibody-drug-conjugates-adc","status":"publish","type":"post","link":"https:\/\/legaladvantage.net\/2026\/05\/antibody-drug-conjugates-adc\/","title":{"rendered":"Antibody-Drug Conjugates (ADC)"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"19867\" class=\"elementor elementor-19867\">\n\t\t\t\t<div class=\"elementor-element elementor-element-65d03b44 e-flex e-con-boxed e-con e-parent\" data-id=\"65d03b44\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2d304d2 elementor-widget elementor-widget-html\" data-id=\"2d304d2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<!-- Legal Advantage ADC Patent Landscape WordPress HTML Component -->\r\n<section aria-label=\"Antibody Drug Conjugates Patent Landscape Report\" class=\"la-adc-report\">\r\n<style>\r\n    .la-adc-report { --adc-blue:#123d66; --adc-blue-2:#1f6f9f; --adc-cyan:#12a4b6; --adc-navy:#0b1f33; --adc-ink:#1d2733; --adc-muted:#637083; --adc-line:#dbe5ee; --adc-soft:#f4f8fb; --adc-soft-2:#eef6f9; --adc-green:#0f8f6f; --adc-orange:#bf6a02; --adc-red:#b73a3a; --adc-purple:#7055a2; color:var(--adc-ink); line-height:1.68; max-width:1120px; margin:0 auto; padding:24px 16px; }\r\n    .la-adc-report * { box-sizing:border-box; }\r\n    .la-adc-report h1,.la-adc-report h2,.la-adc-report h3,.la-adc-report p { margin-top:0; }\r\n    .adc-hero { background:linear-gradient(135deg,#0d3157 0%,#1f6f9f 62%,#15a9b8 100%); color:#fff; border-radius:26px; padding:42px 34px; margin-bottom:28px; box-shadow:0 18px 45px rgba(13,49,87,.16); overflow:hidden; position:relative; }\r\n    .adc-hero:after { content:\"\"; position:absolute; right:-90px; top:-90px; width:260px; height:260px; border-radius:999px; background:rgba(255,255,255,.12); }\r\n    .adc-kicker { text-transform:uppercase; letter-spacing:.12em; font-size:13px; font-weight:700; opacity:.92; margin-bottom:10px; }\r\n    .adc-hero h1 { font-size:clamp(30px,4.2vw,54px); line-height:1.05; margin:0 0 14px; max-width:840px; }\r\n    .adc-hero p { max-width:760px; margin:0; color:rgba(255,255,255,.9); font-size:18px; }\r\n    .adc-meta { display:flex; gap:10px; flex-wrap:wrap; margin-top:22px; }\r\n    .adc-meta span { background:rgba(255,255,255,.14); border:1px solid rgba(255,255,255,.24); padding:7px 12px; border-radius:999px; font-size:13px; }\r\n    .adc-section { background:#fff; border:1px solid var(--adc-line); border-radius:22px; padding:28px; margin:22px 0; box-shadow:0 10px 28px rgba(15,48,82,.07); }\r\n    .adc-section h2 { color:var(--adc-blue); font-size:clamp(24px,3vw,34px); line-height:1.18; margin-bottom:14px; }\r\n    .adc-section h3 { color:var(--adc-navy); font-size:22px; margin:20px 0 10px; }\r\n    .adc-lead { font-size:18px; color:#344353; }\r\n    .adc-summary { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:14px; margin-top:18px; }\r\n    .adc-summary li { list-style:none; background:var(--adc-soft); border-left:5px solid var(--adc-cyan); border-radius:16px; padding:15px 16px; margin:0; }\r\n    .adc-summary ul { padding:0; margin:0; display:contents; }\r\n    .adc-flow { display:grid; grid-template-columns:repeat(5,minmax(0,1fr)); gap:12px; align-items:stretch; margin:20px 0; }\r\n    .adc-flow-card { border:1px solid var(--adc-line); border-radius:18px; padding:16px; background:linear-gradient(180deg,#fff,#f6fbfd); text-align:center; min-height:128px; display:flex; flex-direction:column; justify-content:center; }\r\n    .adc-flow-card strong { color:var(--adc-blue); display:block; font-size:17px; margin-bottom:6px; }\r\n    .adc-flow-card span { color:var(--adc-muted); font-size:14px; }\r\n    .adc-arrow { display:none; }\r\n    .adc-topic-grid { display:grid; grid-template-columns:repeat(4,minmax(0,1fr)); gap:12px; margin-top:18px; }\r\n    .adc-topic { border:1px solid var(--adc-line); background:var(--adc-soft); border-radius:16px; padding:15px; min-height:104px; }\r\n    .adc-topic strong { display:block; color:var(--adc-navy); margin-bottom:8px; }\r\n    .adc-badge { display:inline-flex; align-items:center; justify-content:center; border-radius:999px; padding:5px 11px; font-size:12px; font-weight:800; letter-spacing:.02em; white-space:nowrap; border:1px solid transparent; }\r\n    .adc-badge--core { background:#eaf5ff; color:#155c91; border-color:#b7d9f1; }\r\n    .adc-badge--platform { background:#efeafd; color:#5d4691; border-color:#d2c3f2; }\r\n    .adc-badge--moderate { background:#fff6df; color:#96610b; border-color:#efd188; }\r\n    .adc-badge--emerging { background:#e9f8f0; color:#14734d; border-color:#b9dfcc; }\r\n    .adc-badge--niche { background:#f6edf4; color:#88476d; border-color:#e0bdd2; }\r\n    .adc-badge--primary { background:#e6f6f4; color:#0c6b62; border-color:#a7ddd6; }\r\n    .adc-badge--rank { background:#eef4fb; color:#123d66; border-color:#cbdceb; }\r\n    .adc-badge--region { background:#f2f3f5; color:#344353; border-color:#d8dde4; }\r\n    .adc-table-wrap { overflow-x:auto; margin:18px 0 8px; border:1px solid var(--adc-line); border-radius:18px; }\r\n    .adc-table { width:100%; border-collapse:separate; border-spacing:0; min-width:680px; background:#fff; }\r\n    .adc-table th { background:var(--adc-blue); color:#fff; text-align:left; padding:14px 16px; font-size:14px; letter-spacing:.03em; text-transform:uppercase; }\r\n    .adc-table td { padding:14px 16px; border-top:1px solid var(--adc-line); vertical-align:middle; }\r\n    .adc-table tr:nth-child(even) td { background:#f9fcfe; }\r\n    .adc-bar { height:12px; border-radius:999px; background:#ececec; min-width:140px; overflow:hidden; box-shadow:inset 0 1px 2px rgba(0,0,0,.06); }\r\n    .adc-bar span { display:block; height:100%; border-radius:999px; background:#2e86c1; }\r\n    .adc-bar--blue span { background:#2e86c1; }\r\n    .adc-bar--green span { background:#1a7a4a; }\r\n    .adc-bar--orange span { background:#d68910; }\r\n    .adc-bar--red span { background:#c0392b; }\r\n    .adc-bar--gray span { background:#566573; }\r\n    .adc-chart-table td:first-child { font-weight:700; color:var(--adc-navy); }\r\n    .adc-callout { display:grid; grid-template-columns:54px 1fr; gap:14px; background:linear-gradient(135deg,#eef8fb,#fff); border:1px solid #bfe5ee; border-left:6px solid var(--adc-cyan); border-radius:18px; padding:18px; margin:20px 0; }\r\n    .adc-callout-icon { width:42px; height:42px; border-radius:14px; background:var(--adc-cyan); color:#fff; display:flex; align-items:center; justify-content:center; font-weight:900; }\r\n    .adc-callout strong { display:block; color:var(--adc-blue); text-transform:uppercase; letter-spacing:.05em; font-size:14px; margin-bottom:3px; }\r\n    .adc-caption { color:var(--adc-muted); font-size:14px; margin:8px 0 0; }\r\n    .adc-stat-grid { display:grid; grid-template-columns:repeat(4,minmax(0,1fr)); gap:14px; margin:20px 0; }\r\n    .adc-stat { background:var(--adc-soft); border:1px solid var(--adc-line); border-radius:18px; padding:18px; }\r\n    .adc-stat strong { display:block; color:var(--adc-blue); font-size:28px; line-height:1.1; margin-bottom:6px; }\r\n    .adc-impact { letter-spacing:1px; color:#d68a00; font-size:17px; white-space:nowrap; }\r\n    .adc-footer { background:#0b1f33; color:#dce7f1; border-radius:22px; padding:26px; margin-top:24px; }\r\n    .adc-footer h2 { color:#fff; margin-bottom:10px; font-size:24px; }\r\n    .adc-footer-grid { display:grid; grid-template-columns:1fr 1fr; gap:22px; }\r\n    .adc-small { font-size:13px; color:#758395; }\r\n    @media (max-width:860px) { .adc-summary,.adc-stat-grid,.adc-footer-grid { grid-template-columns:1fr; } .adc-flow { grid-template-columns:1fr; } .adc-topic-grid { grid-template-columns:repeat(2,minmax(0,1fr)); } .adc-section,.adc-hero { padding:22px; } }\r\n    @media (max-width:560px) { .adc-topic-grid { grid-template-columns:1fr; } .adc-table { min-width:620px; } }\r\n  <\/style>\r\n<header class=\"adc-hero\">\r\n<div class=\"adc-kicker\">Legal Advantage LLC | Patent Landscape Report<\/div>\r\n<h1 style=\"color:#fff;\">Antibody-Drug Conjugates (ADC): A Patent Landscape Overview<\/h1>\r\n<p>A structured overview of global ADC patent activity, core technology domains, key jurisdictions, leading assignees, CPC classifications, and influential patent publications from 2020 to 2025.<\/p>\r\n<div class=\"adc-meta\"><span>2020 - 2025<\/span><span>ADC Patent Landscape<\/span><span>Pharma &amp; Biotechnology<\/span><span>legaladvantage.net<\/span><\/div>\r\n<\/header>\r\n<section class=\"adc-section\">\r\n<h2>Executive Summary<\/h2>\r\n<div class=\"adc-stat-grid\">\r\n<div class=\"adc-stat\"><strong>79%<\/strong><span>Increase in ADC patent applications from 2020 to 2024.<\/span><\/div>\r\n<div class=\"adc-stat\"><strong>3,381<\/strong><span>Application peak recorded in 2024.<\/span><\/div>\r\n<div class=\"adc-stat\"><strong>7,143<\/strong><span>Patents under CPC A61P35\/00 for antineoplastic agents.<\/span><\/div>\r\n<div class=\"adc-stat\"><strong>#1<\/strong><span>China leads ADC patent publications globally.<\/span><\/div>\r\n<\/div>\r\n<div class=\"adc-summary\"><ul>\r\n<li>ADC patent applications grew from 1,891 in 2020 to 3,381 in 2024, representing a 79% increase over five years.<\/li>\r\n<li>China leads all jurisdictions in ADC patent publications, followed by WIPO international filings and the United States.<\/li>\r\n<li>Regeneron, Seagen, Genentech, and Daiichi Sankyo hold the largest portfolios; Chinese players such as Jiangsu Hengrui are rapidly expanding.<\/li>\r\n<li>Innovation is concentrated in antibody engineering, linker chemistry, conjugation platforms, and payload design.<\/li>\r\n<\/ul><\/div>\r\n<\/section>\r\n<section class=\"adc-section\">\r\n<h2>1. Introduction<\/h2>\r\n<p class=\"adc-lead\">Antibody-drug conjugates, often called ADCs, have evolved into an important treatment approach, particularly in cancer care. They combine monoclonal antibodies with potent drug payloads to deliver targeted therapy to diseased cells while limiting effects on healthy tissue.<\/p>\r\n<p>This report reviews global patent activity in ADC technologies, with a focus on recent trends in innovation and development. ADC patent protection spans multiple components, including the antibody, linker and conjugation chemistry, payload, formulation, and manufacturing methods. Understanding these layers is essential for evaluating ownership and overlap across technologies.<\/p>\r\n<h3>ADC Architecture - Component Overview<\/h3>\r\n<div class=\"adc-flow\">\r\n<div class=\"adc-flow-card\"><strong>Antibody (mAb)<\/strong><span>Target specificity<\/span><\/div>\r\n<div class=\"adc-flow-card\"><strong>Linker<\/strong><span>Controlled release<\/span><\/div>\r\n<div class=\"adc-flow-card\"><strong>Payload<\/strong><span>Cytotoxic kill<\/span><\/div>\r\n<div class=\"adc-flow-card\"><strong>Conjugation<\/strong><span>Site-specific attach.<\/span><\/div>\r\n<div class=\"adc-flow-card\"><strong>ADC<\/strong><span>Targeted therapy<\/span><\/div>\r\n<\/div>\r\n<p>Patent filings have increased steadily in recent years, with a faster rise in granted patents. Activity is concentrated in major jurisdictions such as China, WIPO international filings, and the United States, with leading portfolios held by companies such as Regeneron, Seagen, Genentech, and Daiichi Sankyo.<\/p>\r\n<\/section>\r\n<section class=\"adc-section\">\r\n<h2>2. Key Research Topics in ADC Patent Literature<\/h2>\r\n<p>The distribution of key research topics across ADC patent literature reveals clear clustering around core themes and emerging specialty areas. Antibody drugs, antibodies or antigens, target cells, disease treatment, and immune-related concepts appear most frequently, forming the foundation of ADC innovation.<\/p>\r\n<div class=\"adc-topic-grid\">\r\n<div class=\"adc-topic\"><strong>Antibody Drugs<\/strong><span class=\"adc-badge adc-badge--core\">Core<\/span><\/div>\r\n<div class=\"adc-topic\"><strong>Target Cells<\/strong><span class=\"adc-badge adc-badge--core\">Core<\/span><\/div>\r\n<div class=\"adc-topic\"><strong>Disease Treatment<\/strong><span class=\"adc-badge adc-badge--core\">Core<\/span><\/div>\r\n<div class=\"adc-topic\"><strong>Ab \/ Antigens<\/strong><span class=\"adc-badge adc-badge--core\">Core<\/span><\/div>\r\n<div class=\"adc-topic\"><strong>Heavy\/Light Chains<\/strong><span class=\"adc-badge adc-badge--platform\">Platform<\/span><\/div>\r\n<div class=\"adc-topic\"><strong>Monoclonal Abs<\/strong><span class=\"adc-badge adc-badge--platform\">Platform<\/span><\/div>\r\n<div class=\"adc-topic\"><strong>Immune Concepts<\/strong><span class=\"adc-badge adc-badge--core\">Core<\/span><\/div>\r\n<div class=\"adc-topic\"><strong>Antibody Structure<\/strong><span class=\"adc-badge adc-badge--platform\">Platform<\/span><\/div>\r\n<div class=\"adc-topic\"><strong>Disease \/ Disorder<\/strong><span class=\"adc-badge adc-badge--moderate\">Moderate<\/span><\/div>\r\n<div class=\"adc-topic\"><strong>Therapeutic Combos<\/strong><span class=\"adc-badge adc-badge--emerging\">Emerging<\/span><\/div>\r\n<div class=\"adc-topic\"><strong>Ligand-Based Drugs<\/strong><span class=\"adc-badge adc-badge--niche\">Niche<\/span><\/div>\r\n<div class=\"adc-topic\"><strong>Targeting Moieties<\/strong><span class=\"adc-badge adc-badge--niche\">Niche<\/span><\/div>\r\n<\/div>\r\n<p class=\"adc-caption\">Figure 1: Distribution of Key Research Topics in ADC Patent Literature - Classified by prevalence tier: Core \u00b7 Platform \u00b7 Moderate \u00b7 Emerging \u00b7 Niche<\/p>\r\n<\/section>\r\n<section class=\"adc-section\">\r\n<h2>3. Key Components of ADC Technology<\/h2>\r\n<p>Antibody-drug conjugates are complex multi-component systems. Each element plays a distinct role in the mechanism of action and carries its own distinct patent landscape. Conjugation chemistry and formulation strategies are also critical dimensions that influence stability, pharmacokinetics, and IP strategy.<\/p>\r\n<div class=\"adc-table-wrap\"><table class=\"adc-table\"><thead><tr><th>ADC Component<\/th><th>Function<\/th><th>Patent Focus Areas<\/th><\/tr><\/thead><tbody><tr><td><strong>Antibody (mAb)<\/strong><\/td><td>Targets cancer cell-surface antigens with high specificity<\/td><td>Sequence claims, CDR engineering, humanization methods<\/td><\/tr><tr><td><strong>Linker<\/strong><\/td><td>Connects antibody to payload; controls drug release in tumor microenvironment<\/td><td>Cleavable and non-cleavable linker chemistry, stability, DAR optimization<\/td><\/tr><tr><td><strong>Cytotoxic Payload<\/strong><\/td><td>Kills cancer cells after internalization of the ADC<\/td><td>Novel toxin scaffolds, payload potency, mechanism of action<\/td><\/tr><tr><td><strong>Conjugation Chemistry<\/strong><\/td><td>Attaches payload to antibody at defined sites<\/td><td>Site-specific conjugation, DAR control, manufacturing process<\/td><\/tr><tr><td><strong>Formulation &amp; Delivery<\/strong><\/td><td>Ensures stability, pharmacokinetics, and bioavailability<\/td><td>Drug product formulations, delivery systems, dosing regimens<\/td><\/tr><\/tbody><\/table><\/div>\r\n<p class=\"adc-caption\">Table 1: Key Components of ADC Technology and Their Patent Focus Areas<\/p>\r\n<\/section>\r\n<section class=\"adc-section\">\r\n<h2>4. Filing Trends: 2020 - 2025<\/h2>\r\n<p>Patent applications increased steadily from 1,891 in 2020 to a peak of 3,381 in 2024, before declining slightly to 2,789 in 2025.<\/p>\r\n<div class=\"adc-table-wrap\"><table class=\"adc-table adc-chart-table\"><thead><tr><th>Year<\/th><th>Applications<\/th><th>Count<\/th><\/tr><\/thead><tbody><tr><td>2020<\/td><td><div aria-label=\"1,891 applications\" class=\"adc-bar adc-bar--blue\"><span style=\"width:56%\"><\/span><\/div><\/td><td><strong>1,891<\/strong><\/td><\/tr><tr><td>2021<\/td><td><div aria-label=\"2,240 applications\" class=\"adc-bar adc-bar--blue\"><span style=\"width:66%\"><\/span><\/div><\/td><td><strong>2,240<\/strong><\/td><\/tr><tr><td>2022<\/td><td><div aria-label=\"2,680 applications\" class=\"adc-bar adc-bar--blue\"><span style=\"width:79%\"><\/span><\/div><\/td><td><strong>2,680<\/strong><\/td><\/tr><tr><td>2023<\/td><td><div aria-label=\"3,050 applications\" class=\"adc-bar adc-bar--blue\"><span style=\"width:90%\"><\/span><\/div><\/td><td><strong>3,050<\/strong><\/td><\/tr><tr><td>2024<\/td><td><div aria-label=\"3,381 applications\" class=\"adc-bar adc-bar--blue\"><span style=\"width:100%\"><\/span><\/div><\/td><td><strong>3,381<\/strong><\/td><\/tr><tr><td>2025<\/td><td><div aria-label=\"2,789 applications\" class=\"adc-bar adc-bar--blue\"><span style=\"width:82%\"><\/span><\/div><\/td><td><strong>2,789<\/strong><\/td><\/tr><\/tbody><\/table><\/div>\r\n<p class=\"adc-caption\">Figure 2: Year-by-Year Growth of ADC Patent Applications (2020-2025)<\/p>\r\n<div class=\"adc-callout\"><div class=\"adc-callout-icon\">!<\/div><div><strong>Key Insight<\/strong><p>The slight decline in applications in 2025 may reflect market consolidation and tightening claim drafting practices rather than a reduction in innovation activity.<\/p><\/div><\/div>\r\n<\/section>\r\n<section class=\"adc-section\">\r\n<h2>5. Worldwide Distribution of Patent Activity<\/h2>\r\n<p>The geographic distribution of ADC patent activity reflects both the locations of the major innovators and the commercial markets they are seeking to protect. China leads in absolute publication volume, followed by WIPO international (PCT) filings and the United States.<\/p>\r\n<div class=\"adc-table-wrap\"><table class=\"adc-table adc-chart-table\"><thead><tr><th>Jurisdiction<\/th><th>Relative Patent Activity<\/th><th>Rank<\/th><\/tr><\/thead><tbody><tr><td>China (CN)<\/td><td><div aria-label=\"China (CN) relative patent activity\" class=\"adc-bar adc-bar--blue\"><span style=\"width:100%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#1<\/span><\/td><\/tr><tr><td>WIPO (PCT)<\/td><td><div aria-label=\"WIPO (PCT) relative patent activity\" class=\"adc-bar adc-bar--blue\"><span style=\"width:84%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#2<\/span><\/td><\/tr><tr><td>United States<\/td><td><div aria-label=\"United States relative patent activity\" class=\"adc-bar adc-bar--blue\"><span style=\"width:76%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#3<\/span><\/td><\/tr><tr><td>Japan (JP)<\/td><td><div aria-label=\"Japan (JP) relative patent activity\" class=\"adc-bar adc-bar--green\"><span style=\"width:61%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#4<\/span><\/td><\/tr><tr><td>EPO (EP)<\/td><td><div aria-label=\"EPO (EP) relative patent activity\" class=\"adc-bar adc-bar--green\"><span style=\"width:55%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#5<\/span><\/td><\/tr><tr><td>Australia (AU)<\/td><td><div aria-label=\"Australia (AU) relative patent activity\" class=\"adc-bar adc-bar--orange\"><span style=\"width:38%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#6<\/span><\/td><\/tr><tr><td>South Korea (KR)<\/td><td><div aria-label=\"South Korea (KR) relative patent activity\" class=\"adc-bar adc-bar--orange\"><span style=\"width:34%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#7<\/span><\/td><\/tr><tr><td>Canada (CA)<\/td><td><div aria-label=\"Canada (CA) relative patent activity\" class=\"adc-bar adc-bar--orange\"><span style=\"width:29%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#8<\/span><\/td><\/tr><tr><td>Taiwan (TW)<\/td><td><div aria-label=\"Taiwan (TW) relative patent activity\" class=\"adc-bar adc-bar--red\"><span style=\"width:23%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#9<\/span><\/td><\/tr><tr><td>India (IN)<\/td><td><div aria-label=\"India (IN) relative patent activity\" class=\"adc-bar adc-bar--red\"><span style=\"width:19%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#10<\/span><\/td><\/tr><\/tbody><\/table><\/div>\r\n<p class=\"adc-caption\">Figure 3: Top 10 Jurisdictions by ADC Patent Publications (2020-2025) - Bar length reflects relative publication volume<\/p>\r\n<\/section>\r\n<section class=\"adc-section\">\r\n<h2>6. Top Players in ADC Technologies<\/h2>\r\n<p>Patent portfolio leadership in the ADC space reflects significant investment by both established pharmaceutical companies and emerging biotechnology players. Regeneron leads, followed by Seagen, Genentech, and Daiichi Sankyo, reflecting deep expertise in antibody engineering and oncology.<\/p>\r\n<div class=\"adc-table-wrap\"><table class=\"adc-table adc-chart-table\"><thead><tr><th>Assignee<\/th><th>Patent Portfolio (Relative)<\/th><th>Rank<\/th><th>Region<\/th><\/tr><\/thead><tbody><tr><td>Regeneron<\/td><td><div aria-label=\"Regeneron relative portfolio\" class=\"adc-bar adc-bar--blue\"><span style=\"width:100%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#1<\/span><\/td><td><span class=\"adc-badge adc-badge--region\">USA<\/span><\/td><\/tr><tr><td>Seagen<\/td><td><div aria-label=\"Seagen relative portfolio\" class=\"adc-bar adc-bar--blue\"><span style=\"width:92%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#2<\/span><\/td><td><span class=\"adc-badge adc-badge--region\">USA<\/span><\/td><\/tr><tr><td>Genentech \/ Roche<\/td><td><div aria-label=\"Genentech \/ Roche relative portfolio\" class=\"adc-bar adc-bar--blue\"><span style=\"width:86%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#3<\/span><\/td><td><span class=\"adc-badge adc-badge--region\">USA\/EU<\/span><\/td><\/tr><tr><td>Daiichi Sankyo<\/td><td><div aria-label=\"Daiichi Sankyo relative portfolio\" class=\"adc-bar adc-bar--green\"><span style=\"width:80%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#4<\/span><\/td><td><span class=\"adc-badge adc-badge--region\">Japan<\/span><\/td><\/tr><tr><td>AstraZeneca<\/td><td><div aria-label=\"AstraZeneca relative portfolio\" class=\"adc-bar adc-bar--green\"><span style=\"width:70%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#5<\/span><\/td><td><span class=\"adc-badge adc-badge--region\">UK\/EU<\/span><\/td><\/tr><tr><td>Jiangsu Hengrui<\/td><td><div aria-label=\"Jiangsu Hengrui relative portfolio\" class=\"adc-bar adc-bar--orange\"><span style=\"width:61%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#6<\/span><\/td><td><span class=\"adc-badge adc-badge--region\">China<\/span><\/td><\/tr><tr><td>Sichuan Kelun Biotech<\/td><td><div aria-label=\"Sichuan Kelun Biotech relative portfolio\" class=\"adc-bar adc-bar--orange\"><span style=\"width:55%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#7<\/span><\/td><td><span class=\"adc-badge adc-badge--region\">China<\/span><\/td><\/tr><tr><td>ImmunoGen<\/td><td><div aria-label=\"ImmunoGen relative portfolio\" class=\"adc-bar adc-bar--red\"><span style=\"width:48%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#8<\/span><\/td><td><span class=\"adc-badge adc-badge--region\">USA<\/span><\/td><\/tr><tr><td>ADC Therapeutics<\/td><td><div aria-label=\"ADC Therapeutics relative portfolio\" class=\"adc-bar adc-bar--red\"><span style=\"width:42%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#9<\/span><\/td><td><span class=\"adc-badge adc-badge--region\">Switzerland<\/span><\/td><\/tr><tr><td>Academic Institutions<\/td><td><div aria-label=\"Academic Institutions relative portfolio\" class=\"adc-bar adc-bar--gray\"><span style=\"width:36%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--rank\">#10<\/span><\/td><td><span class=\"adc-badge adc-badge--region\">Global<\/span><\/td><\/tr><\/tbody><\/table><\/div>\r\n<p class=\"adc-caption\">Figure 4: Top 10 Current Assignees by ADC Patent Portfolio (2020-2025) - Bar length reflects relative patent count.<\/p>\r\n<\/section>\r\n<section class=\"adc-section\">\r\n<h2>7. Technology Sub-Domain Analysis<\/h2>\r\n<p>ADC patent activity spans multiple technology sub-domains across the IPC\/CPC classification system. Pharmaceuticals and biotechnology account for the largest share of patents, reflecting the core role of drug development and biological engineering.<\/p>\r\n<div class=\"adc-table-wrap\"><table class=\"adc-table adc-chart-table\"><thead><tr><th>Sub-Domain<\/th><th>Share of ADC Patent Activity<\/th><th>Tier<\/th><\/tr><\/thead><tbody><tr><td>Pharmaceuticals &amp; Biotech<\/td><td><div aria-label=\"Pharmaceuticals &amp; Biotech share of activity\" class=\"adc-bar adc-bar--blue\"><span style=\"width:100%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--primary\">Primary<\/span><\/td><\/tr><tr><td>Biological Materials<\/td><td><div aria-label=\"Biological Materials share of activity\" class=\"adc-bar adc-bar--blue\"><span style=\"width:84%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--primary\">Primary<\/span><\/td><\/tr><tr><td>Organic Fine Chemistry<\/td><td><div aria-label=\"Organic Fine Chemistry share of activity\" class=\"adc-bar adc-bar--green\"><span style=\"width:70%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--core\">Core<\/span><\/td><\/tr><tr><td>Diagnostic Methods<\/td><td><div aria-label=\"Diagnostic Methods share of activity\" class=\"adc-bar adc-bar--green\"><span style=\"width:62%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--core\">Core<\/span><\/td><\/tr><tr><td>Medical Technology<\/td><td><div aria-label=\"Medical Technology share of activity\" class=\"adc-bar adc-bar--orange\"><span style=\"width:45%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--emerging\">Emerging<\/span><\/td><\/tr><tr><td>Nanotechnology<\/td><td><div aria-label=\"Nanotechnology share of activity\" class=\"adc-bar adc-bar--orange\"><span style=\"width:35%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--emerging\">Emerging<\/span><\/td><\/tr><tr><td>Macromolecular Chemistry<\/td><td><div aria-label=\"Macromolecular Chemistry share of activity\" class=\"adc-bar adc-bar--red\"><span style=\"width:24%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--niche\">Niche<\/span><\/td><\/tr><tr><td>Polymers<\/td><td><div aria-label=\"Polymers share of activity\" class=\"adc-bar adc-bar--red\"><span style=\"width:18%\"><\/span><\/div><\/td><td><span class=\"adc-badge adc-badge--niche\">Niche<\/span><\/td><\/tr><\/tbody><\/table><\/div>\r\n<p class=\"adc-caption\">Figure 5: ADC Patents by Technology Sub-Domain (2020-2025) - Bar length reflects proportional share of total patent activity<\/p>\r\n<\/section>\r\n<section class=\"adc-section\">\r\n<h2>8. CPC Classification Analysis<\/h2>\r\n<p>The Cooperative Patent Classification (CPC) system provides granular insight into the specific technology areas driving ADC innovation. The most frequently occurring CPC codes confirm the primacy of oncology and highlight the depth of patent activity in antibody engineering and conjugation chemistry.<\/p>\r\n<div class=\"adc-table-wrap\"><table class=\"adc-table adc-chart-table\"><thead><tr><th>CPC Code<\/th><th>Patent Count<\/th><th>Count<\/th><\/tr><\/thead><tbody><tr><td><strong>A61P35\/00<\/strong><\/td><td><div aria-label=\"A61P35\/00 patent count 7,143\" class=\"adc-bar adc-bar--blue\"><span style=\"width:100%\"><\/span><\/div><\/td><td><strong>7,143<\/strong><\/td><\/tr><tr><td><strong>A61K2039\/505<\/strong><\/td><td><div aria-label=\"A61K2039\/505 patent count 4,088\" class=\"adc-bar adc-bar--blue\"><span style=\"width:57%\"><\/span><\/div><\/td><td><strong>4,088<\/strong><\/td><\/tr><tr><td><strong>C07K2317\/92<\/strong><\/td><td><div aria-label=\"C07K2317\/92 patent count 3,282\" class=\"adc-bar adc-bar--green\"><span style=\"width:46%\"><\/span><\/div><\/td><td><strong>3,282<\/strong><\/td><\/tr><tr><td><strong>A61K47\/6849<\/strong><\/td><td><div aria-label=\"A61K47\/6849 patent count 2,801\" class=\"adc-bar adc-bar--green\"><span style=\"width:39%\"><\/span><\/div><\/td><td><strong>2,801<\/strong><\/td><\/tr><tr><td><strong>C07K2317\/565<\/strong><\/td><td><div aria-label=\"C07K2317\/565 patent count 2,605\" class=\"adc-bar adc-bar--green\"><span style=\"width:36%\"><\/span><\/div><\/td><td><strong>2,605<\/strong><\/td><\/tr><tr><td><strong>C07K2317\/24<\/strong><\/td><td><div aria-label=\"C07K2317\/24 patent count 2,417\" class=\"adc-bar adc-bar--orange\"><span style=\"width:34%\"><\/span><\/div><\/td><td><strong>2,417<\/strong><\/td><\/tr><tr><td><strong>C07K2317\/76<\/strong><\/td><td><div aria-label=\"C07K2317\/76 patent count 1,932\" class=\"adc-bar adc-bar--orange\"><span style=\"width:27%\"><\/span><\/div><\/td><td><strong>1,932<\/strong><\/td><\/tr><tr><td><strong>A61K47\/6803<\/strong><\/td><td><div aria-label=\"A61K47\/6803 patent count 1,863\" class=\"adc-bar adc-bar--orange\"><span style=\"width:26%\"><\/span><\/div><\/td><td><strong>1,863<\/strong><\/td><\/tr><tr><td><strong>C07K2317\/31<\/strong><\/td><td><div aria-label=\"C07K2317\/31 patent count 1,822\" class=\"adc-bar adc-bar--red\"><span style=\"width:26%\"><\/span><\/div><\/td><td><strong>1,822<\/strong><\/td><\/tr><tr><td><strong>A61K47\/6889<\/strong><\/td><td><div aria-label=\"A61K47\/6889 patent count 1,578\" class=\"adc-bar adc-bar--red\"><span style=\"width:22%\"><\/span><\/div><\/td><td><strong>1,578<\/strong><\/td><\/tr><\/tbody><\/table><\/div>\r\n<p class=\"adc-caption\">Figure 6: Top 10 CPC Codes in ADC Patent Filings by Patent Count (2020-2025)<\/p>\r\n<div class=\"adc-table-wrap\"><table class=\"adc-table\"><thead><tr><th>CPC Code<\/th><th>Description<\/th><th>Total Patents<\/th><\/tr><\/thead><tbody><tr><td><strong>A61P35\/00<\/strong><\/td><td>Antineoplastic agents<\/td><td>7,143<\/td><\/tr><tr><td><strong>A61K2039\/505<\/strong><\/td><td>Comprising antibodies<\/td><td>4,088<\/td><\/tr><tr><td><strong>C07K2317\/92<\/strong><\/td><td>Affinity (KD), association rate, EC50 value<\/td><td>3,282<\/td><\/tr><tr><td><strong>A61K47\/6849<\/strong><\/td><td>Antibody targeting a receptor or cell surface antigen<\/td><td>2,801<\/td><\/tr><tr><td><strong>C07K2317\/565<\/strong><\/td><td>Complementarity determining region (CDR)<\/td><td>2,605<\/td><\/tr><tr><td><strong>C07K2317\/24<\/strong><\/td><td>Chimeric, humanized or veneered antibodies<\/td><td>2,417<\/td><\/tr><tr><td><strong>C07K2317\/76<\/strong><\/td><td>Antagonist effect on antigen, e.g. neutralization<\/td><td>1,932<\/td><\/tr><tr><td><strong>A61K47\/6803<\/strong><\/td><td>Drugs conjugated to an antibody or immunoglobulin<\/td><td>1,863<\/td><\/tr><tr><td><strong>C07K2317\/31<\/strong><\/td><td>Multispecific antibodies<\/td><td>1,822<\/td><\/tr><tr><td><strong>A61K47\/6889<\/strong><\/td><td>Linker or spacer conjugates with acid-labile release<\/td><td>1,578<\/td><\/tr><\/tbody><\/table><\/div>\r\n<p class=\"adc-caption\">Table 2: Definitions of Top 10 CPC Classification Codes in ADC Patent Filings<\/p>\r\n<div class=\"adc-callout\"><div class=\"adc-callout-icon\">\u2605<\/div><div><strong>Oncology Dominance<\/strong><p>A61P35\/00, antineoplastic agents, leads all CPC codes with 7,143 patents - more than 70% more than the second-ranked code - confirming that oncology remains the primary focus of ADC development. A61K47\/6803 and A61K47\/6889 together cover ADC conjugation and linker platforms, reflecting their growing strategic importance.<\/p><\/div><\/div>\r\n<\/section>\r\n<section class=\"adc-section\">\r\n<h2>9. Highly Influential Patent Publications<\/h2>\r\n<p>Forward citation counts serve as an indicator of both scientific and strategic impact in patent analysis. The most highly cited ADC-related patent records reveal the foundations upon which the broader landscape is built. Dyne Therapeutics accounts for most of these highly cited patents, primarily focused on its anti-transferrin receptor antibody platform and muscle-targeting complexes for rare neuromuscular diseases.<\/p>\r\n<p>MediLink Therapeutics also appears in the top cited records, highlighting the growing influence of Chinese players in ADC innovation. The presence of a CureVac coronavirus vaccine patent among the most cited records reflects increasing cross-technology interest between mRNA platforms and ADC delivery approaches.<\/p>\r\n<div class=\"adc-table-wrap\"><table class=\"adc-table\"><thead><tr><th>Assignee<\/th><th>Technology Focus<\/th><th>Indication<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td>Dyne Therapeutics<\/td><td>Anti-TfR1 antibody platform; muscle-targeting complexes<\/td><td>FSHD, DMD, DM1<\/td><td><span class=\"adc-impact\">\u2605\u2605\u2605\u2605\u2605<\/span><\/td><\/tr><tr><td>Dyne Therapeutics<\/td><td>Antibody-oligonucleotide conjugate (AOC) delivery<\/td><td>Rare neuromuscular<\/td><td><span class=\"adc-impact\">\u2605\u2605\u2605\u2605\u2605<\/span><\/td><\/tr><tr><td>Dyne Therapeutics<\/td><td>Antibody conjugate with GalNAc-siRNA<\/td><td>Rare neuromuscular<\/td><td><span class=\"adc-impact\">\u2605\u2605\u2605\u2605\u2606<\/span><\/td><\/tr><tr><td>MediLink Therapeutics<\/td><td>Bioactive substance conjugate (Chinese ADC platform)<\/td><td>Oncology<\/td><td><span class=\"adc-impact\">\u2605\u2605\u2605\u2605\u2606<\/span><\/td><\/tr><tr><td>Dyne Therapeutics<\/td><td>Transferrin receptor targeting moieties<\/td><td>Rare neuromuscular<\/td><td><span class=\"adc-impact\">\u2605\u2605\u2605\u2605\u2606<\/span><\/td><\/tr><tr><td>CureVac<\/td><td>SARS-CoV-2 mRNA vaccine platform; cross-tech interest<\/td><td>COVID-19 \/ mRNA<\/td><td><span class=\"adc-impact\">\u2605\u2605\u2605\u2606\u2606<\/span><\/td><\/tr><tr><td>Dyne Therapeutics<\/td><td>Conjugate delivery to skeletal muscle tissue<\/td><td>Rare neuromuscular<\/td><td><span class=\"adc-impact\">\u2605\u2605\u2605\u2606\u2606<\/span><\/td><\/tr><tr><td>Dyne Therapeutics<\/td><td>Half-life extension via IgG Fc domain modification<\/td><td>Rare neuromuscular<\/td><td><span class=\"adc-impact\">\u2605\u2605\u2605\u2606\u2606<\/span><\/td><\/tr><\/tbody><\/table><\/div>\r\n<p class=\"adc-caption\">Figure 7: Top Most-Cited ADC-Related Patent Records by Forward Citations (2020-2025) - Star rating is an illustrative citation impact indicator.<\/p>\r\n<\/section>\r\n<section class=\"adc-section\">\r\n<h2>10. Conclusion<\/h2>\r\n<p>The ADC patent landscape is experiencing rapid growth and increasing competition. Patent applications rose from 1,891 in 2020 to 3,381 in 2024, with grants growing even faster, indicating a maturing intellectual property environment. China and the United States remain the leading jurisdictions, followed by PCT filings and Japan.<\/p>\r\n<p>Leading portfolios are held by Regeneron, Seagen, Genentech, and Daiichi Sankyo. The presence of Chinese companies such as Jiangsu Hengrui and Sichuan Kelun Biotech highlights increasing global competition. Academic institutions continue to contribute to foundational innovations that underpin the broader landscape.<\/p>\r\n<p>CPC classifications confirm a strong focus on oncology, with significant activity in antibody engineering, linker design, conjugation chemistry, and payload development. This reflects continued advancement beyond early-generation ADC technologies toward more sophisticated, differentiated platforms.<\/p>\r\n<div class=\"adc-callout\"><div class=\"adc-callout-icon\">\u2192<\/div><div><strong>Strategic Implications<\/strong><p>A clear understanding of the ADC patent landscape is essential for informed decision-making, particularly in freedom-to-operate analysis, portfolio development, and licensing strategy. Legal Advantage LLC provides comprehensive patent landscape searches, FTO analyses, and IP strategy support across the pharmaceutical and biotechnology sectors.<\/p><\/div><\/div>\r\n<\/section>\r\n<footer class=\"adc-footer\">\r\n<div class=\"adc-footer-grid\">\r\n<div><h2>About Legal Advantage LLC<\/h2><p>Legal Advantage LLC provides patent search, patent landscape analysis, FTO searches, patent drafting, patent illustrations, and IP legal support services to law firms and corporations worldwide. Visit legaladvantage.net or contact Inbox@legaladvantage.net | (301) 450-2161<\/p><\/div>\r\n<div><h2>Disclaimer<\/h2><p>This article is provided for informational and educational purposes only. It does not constitute legal, financial, or professional advice. Readers are encouraged to consult a qualified patent attorney for specific guidance on patents and regulatory matters.<\/p><\/div>\r\n<\/div>\r\n<!--<p class=\"adc-small\">\u00a9 2026 Legal Advantage LLC | Confidential - For informational use only | ADC Patent Landscape 2020 - 2025<\/p>-->\r\n<\/footer>\r\n<\/section>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Legal Advantage LLC | Patent Landscape Report Antibody-Drug Conjugates (ADC): A Patent Landscape Overview A structured overview of global ADC patent activity, core technology domains, key jurisdictions, leading assignees, CPC classifications, and influential patent publications from 2020 to 2025. 2020 &#8211; 2025ADC Patent LandscapePharma &amp; Biotechnologylegaladvantage.net Executive Summary 79%Increase in ADC patent applications from 2020 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":19869,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","footnotes":""},"categories":[],"tags":[],"class_list":["post-19867","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innovation at Light Speed Tracking the Surge in Quantum Patent Filings<\/title>\n<meta name=\"description\" content=\"As quantum computing transitions from the realm of research to real-world application, the global race for intellectual property dominance has become a defining feature of this technological revolution. Patents in this space have emerged as powerful strategic assets granting not only legal protection but also signalling innovation leadership and investment potential.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/legaladvantage.net\/2026\/05\/antibody-drug-conjugates-adc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovation at Light Speed Tracking the Surge in Quantum Patent Filings\" \/>\n<meta property=\"og:description\" content=\"As quantum computing transitions from the realm of research to real-world application, the global race for intellectual property dominance has become a defining feature of this technological revolution. Patents in this space have emerged as powerful strategic assets granting not only legal protection but also signalling innovation leadership and investment potential.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/legaladvantage.net\/2026\/05\/antibody-drug-conjugates-adc\/\" \/>\n<meta property=\"og:site_name\" content=\"Legal Advantage\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-27T06:58:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-27T07:07:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/legaladvantage.net\/wp-content\/uploads\/2026\/05\/Antibody-Drug-Conjugates-ADC.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"560\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"legaladvantage\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"legaladvantage\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/legaladvantage.net\\\/2026\\\/05\\\/antibody-drug-conjugates-adc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/legaladvantage.net\\\/2026\\\/05\\\/antibody-drug-conjugates-adc\\\/\"},\"author\":{\"name\":\"legaladvantage\",\"@id\":\"https:\\\/\\\/legaladvantage.net\\\/#\\\/schema\\\/person\\\/265948e08c42b20a73df94b3f39f4e54\"},\"headline\":\"Antibody-Drug Conjugates (ADC)\",\"datePublished\":\"2026-05-27T06:58:40+00:00\",\"dateModified\":\"2026-05-27T07:07:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/legaladvantage.net\\\/2026\\\/05\\\/antibody-drug-conjugates-adc\\\/\"},\"wordCount\":1495,\"image\":{\"@id\":\"https:\\\/\\\/legaladvantage.net\\\/2026\\\/05\\\/antibody-drug-conjugates-adc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/legaladvantage.net\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Antibody-Drug-Conjugates-ADC.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/legaladvantage.net\\\/2026\\\/05\\\/antibody-drug-conjugates-adc\\\/\",\"url\":\"https:\\\/\\\/legaladvantage.net\\\/2026\\\/05\\\/antibody-drug-conjugates-adc\\\/\",\"name\":\"Innovation at Light Speed Tracking the Surge in Quantum Patent Filings\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/legaladvantage.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/legaladvantage.net\\\/2026\\\/05\\\/antibody-drug-conjugates-adc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/legaladvantage.net\\\/2026\\\/05\\\/antibody-drug-conjugates-adc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/legaladvantage.net\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Antibody-Drug-Conjugates-ADC.jpg\",\"datePublished\":\"2026-05-27T06:58:40+00:00\",\"dateModified\":\"2026-05-27T07:07:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/legaladvantage.net\\\/#\\\/schema\\\/person\\\/265948e08c42b20a73df94b3f39f4e54\"},\"description\":\"As quantum computing transitions from the realm of research to real-world application, the global race for intellectual property dominance has become a defining feature of this technological revolution. Patents in this space have emerged as powerful strategic assets granting not only legal protection but also signalling innovation leadership and investment potential.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/legaladvantage.net\\\/2026\\\/05\\\/antibody-drug-conjugates-adc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/legaladvantage.net\\\/2026\\\/05\\\/antibody-drug-conjugates-adc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/legaladvantage.net\\\/2026\\\/05\\\/antibody-drug-conjugates-adc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/legaladvantage.net\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Antibody-Drug-Conjugates-ADC.jpg\",\"contentUrl\":\"https:\\\/\\\/legaladvantage.net\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Antibody-Drug-Conjugates-ADC.jpg\",\"width\":1000,\"height\":560},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/legaladvantage.net\\\/2026\\\/05\\\/antibody-drug-conjugates-adc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/legaladvantage.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antibody-Drug Conjugates (ADC)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/legaladvantage.net\\\/#website\",\"url\":\"https:\\\/\\\/legaladvantage.net\\\/\",\"name\":\"Legal Advantage\",\"description\":\"Intellectual Property &amp; Legal Support Services\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/legaladvantage.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/legaladvantage.net\\\/#\\\/schema\\\/person\\\/265948e08c42b20a73df94b3f39f4e54\",\"name\":\"legaladvantage\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/58b4c8871c8c764275b19a20cd779f8ced96d8e492b1c675a59645896eaa64d3?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/58b4c8871c8c764275b19a20cd779f8ced96d8e492b1c675a59645896eaa64d3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/58b4c8871c8c764275b19a20cd779f8ced96d8e492b1c675a59645896eaa64d3?s=96&d=mm&r=g\",\"caption\":\"legaladvantage\"},\"sameAs\":[\"https:\\\/\\\/legaladvantage.net\"],\"url\":\"https:\\\/\\\/legaladvantage.net\\\/author\\\/legaladvantage\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innovation at Light Speed Tracking the Surge in Quantum Patent Filings","description":"As quantum computing transitions from the realm of research to real-world application, the global race for intellectual property dominance has become a defining feature of this technological revolution. Patents in this space have emerged as powerful strategic assets granting not only legal protection but also signalling innovation leadership and investment potential.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/legaladvantage.net\/2026\/05\/antibody-drug-conjugates-adc\/","og_locale":"en_US","og_type":"article","og_title":"Innovation at Light Speed Tracking the Surge in Quantum Patent Filings","og_description":"As quantum computing transitions from the realm of research to real-world application, the global race for intellectual property dominance has become a defining feature of this technological revolution. Patents in this space have emerged as powerful strategic assets granting not only legal protection but also signalling innovation leadership and investment potential.","og_url":"https:\/\/legaladvantage.net\/2026\/05\/antibody-drug-conjugates-adc\/","og_site_name":"Legal Advantage","article_published_time":"2026-05-27T06:58:40+00:00","article_modified_time":"2026-05-27T07:07:11+00:00","og_image":[{"width":1000,"height":560,"url":"https:\/\/legaladvantage.net\/wp-content\/uploads\/2026\/05\/Antibody-Drug-Conjugates-ADC.jpg","type":"image\/jpeg"}],"author":"legaladvantage","twitter_card":"summary_large_image","twitter_misc":{"Written by":"legaladvantage","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/legaladvantage.net\/2026\/05\/antibody-drug-conjugates-adc\/#article","isPartOf":{"@id":"https:\/\/legaladvantage.net\/2026\/05\/antibody-drug-conjugates-adc\/"},"author":{"name":"legaladvantage","@id":"https:\/\/legaladvantage.net\/#\/schema\/person\/265948e08c42b20a73df94b3f39f4e54"},"headline":"Antibody-Drug Conjugates (ADC)","datePublished":"2026-05-27T06:58:40+00:00","dateModified":"2026-05-27T07:07:11+00:00","mainEntityOfPage":{"@id":"https:\/\/legaladvantage.net\/2026\/05\/antibody-drug-conjugates-adc\/"},"wordCount":1495,"image":{"@id":"https:\/\/legaladvantage.net\/2026\/05\/antibody-drug-conjugates-adc\/#primaryimage"},"thumbnailUrl":"https:\/\/legaladvantage.net\/wp-content\/uploads\/2026\/05\/Antibody-Drug-Conjugates-ADC.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/legaladvantage.net\/2026\/05\/antibody-drug-conjugates-adc\/","url":"https:\/\/legaladvantage.net\/2026\/05\/antibody-drug-conjugates-adc\/","name":"Innovation at Light Speed Tracking the Surge in Quantum Patent Filings","isPartOf":{"@id":"https:\/\/legaladvantage.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/legaladvantage.net\/2026\/05\/antibody-drug-conjugates-adc\/#primaryimage"},"image":{"@id":"https:\/\/legaladvantage.net\/2026\/05\/antibody-drug-conjugates-adc\/#primaryimage"},"thumbnailUrl":"https:\/\/legaladvantage.net\/wp-content\/uploads\/2026\/05\/Antibody-Drug-Conjugates-ADC.jpg","datePublished":"2026-05-27T06:58:40+00:00","dateModified":"2026-05-27T07:07:11+00:00","author":{"@id":"https:\/\/legaladvantage.net\/#\/schema\/person\/265948e08c42b20a73df94b3f39f4e54"},"description":"As quantum computing transitions from the realm of research to real-world application, the global race for intellectual property dominance has become a defining feature of this technological revolution. Patents in this space have emerged as powerful strategic assets granting not only legal protection but also signalling innovation leadership and investment potential.","breadcrumb":{"@id":"https:\/\/legaladvantage.net\/2026\/05\/antibody-drug-conjugates-adc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/legaladvantage.net\/2026\/05\/antibody-drug-conjugates-adc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/legaladvantage.net\/2026\/05\/antibody-drug-conjugates-adc\/#primaryimage","url":"https:\/\/legaladvantage.net\/wp-content\/uploads\/2026\/05\/Antibody-Drug-Conjugates-ADC.jpg","contentUrl":"https:\/\/legaladvantage.net\/wp-content\/uploads\/2026\/05\/Antibody-Drug-Conjugates-ADC.jpg","width":1000,"height":560},{"@type":"BreadcrumbList","@id":"https:\/\/legaladvantage.net\/2026\/05\/antibody-drug-conjugates-adc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/legaladvantage.net\/"},{"@type":"ListItem","position":2,"name":"Antibody-Drug Conjugates (ADC)"}]},{"@type":"WebSite","@id":"https:\/\/legaladvantage.net\/#website","url":"https:\/\/legaladvantage.net\/","name":"Legal Advantage","description":"Intellectual Property &amp; Legal Support Services","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/legaladvantage.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/legaladvantage.net\/#\/schema\/person\/265948e08c42b20a73df94b3f39f4e54","name":"legaladvantage","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/58b4c8871c8c764275b19a20cd779f8ced96d8e492b1c675a59645896eaa64d3?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/58b4c8871c8c764275b19a20cd779f8ced96d8e492b1c675a59645896eaa64d3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/58b4c8871c8c764275b19a20cd779f8ced96d8e492b1c675a59645896eaa64d3?s=96&d=mm&r=g","caption":"legaladvantage"},"sameAs":["https:\/\/legaladvantage.net"],"url":"https:\/\/legaladvantage.net\/author\/legaladvantage\/"}]}},"_links":{"self":[{"href":"https:\/\/legaladvantage.net\/wp-json\/wp\/v2\/posts\/19867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/legaladvantage.net\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/legaladvantage.net\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/legaladvantage.net\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/legaladvantage.net\/wp-json\/wp\/v2\/comments?post=19867"}],"version-history":[{"count":10,"href":"https:\/\/legaladvantage.net\/wp-json\/wp\/v2\/posts\/19867\/revisions"}],"predecessor-version":[{"id":19878,"href":"https:\/\/legaladvantage.net\/wp-json\/wp\/v2\/posts\/19867\/revisions\/19878"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/legaladvantage.net\/wp-json\/wp\/v2\/media\/19869"}],"wp:attachment":[{"href":"https:\/\/legaladvantage.net\/wp-json\/wp\/v2\/media?parent=19867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/legaladvantage.net\/wp-json\/wp\/v2\/categories?post=19867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/legaladvantage.net\/wp-json\/wp\/v2\/tags?post=19867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}